Anticoagulant treatment of venous thromboembolism in pregnant women

Venous thromboembolism (VTE), in particular pulmonary embolism (PE), remains the leading cause of death among pregnant women. Low-molecular-weight heparin (LMWH), with preference for therapeutic doses given twice daily according to European guidelines, is drug choice treatment VTE pregnancy and puerperium. The recommended dose calculated on early body weight. Evidence support anti-Xa monitoring weak. Unfractionated (UFH) multiple activated partial thromboplastin time measurements still used acute high-risk PE. American experts have suggested considering initial outpatient therapy over hospital admission also women low-risk VTE, but suggest adopting such a strategy selectively, example isolated distal leg thrombosis. Scheduled delivery prior discontinuation anticoagulant who received LMWH restart 4–6 h after vaginal birth 6–12 cesarean delivery. It that UFH, LMWH, warfarin, acenocoumarol, or fondaparinux, not direct-acting oral anticoagulants, should be breastfeeding This review summarizes key messages from current guidelines mainly based low-quality evidence expert consensus.